Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive
environment for tumor growth, and its blockade with directed monoclonal antibodies (anti …

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor belonging to
the CD28 immunoglobulin subfamily, expressed primarily by T-cells. Its ligands, CD80 and …

Background Patients with esophageal cancer are confronted with high mortality rates.
Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma …

Resistance to radiotherapy is a major barrier during cancer treatment. Here using genome-
scale CRISPR/Cas9 screening, we identify CD274 gene, which encodes PD-L1, to confer …

Fucosylation is a post-translational modification of glycans, proteins, and lipids that is
responsible for many biological processes. Fucose conjugation via α (1, 2), α (1, 3), α (1, 4) …

Recent advances in cancer immunology have enabled the discovery of promising
immunotherapies for various malignancies that have shifted the cancer treatment paradigm …

Cancer immunotherapies, including immune checkpoint inhibitors and immune pathway–
targeted therapies, are promising clinical strategies for treating cancer. However, drug …

Cancer immunotherapy is a highly successful and rapidly evolving treatment modality that
works by augmenting the body's own immune system. While various immune stimulation …

Clinical features of idiosyncratic drug induced liver injury (DILI) are well described in cases
that have been assessed for causality using the Roussel Uclaf Causality Assessment …